Firm cofounder to debate use of synthetic intelligence and machine studying purposes for precision drugs in neurology
BOSTON, Jan. 24, 2023 /PRNewswire/ — Beacon Biosignals CEO and co-founder Jacob Donoghue, MD, Ph.D., can be talking on the Precision Drugs World Convention (PMWC) 2023 being held in Silicon Valley from Jan. 25-27, the corporate introduced immediately.
The PMWC is the foremost precision drugs convention, bringing collectively greater than 2,500 acknowledged leaders, high world researchers, medical professionals and innovators in an effort to speed up the event and unfold of precision drugs. It supplies a discussion board for the change of details about the newest advances in expertise, scientific implementation, analysis, and in all features associated to the regulatory and reimbursement sectors.
Dr. Donoghue can be a part of a panel session titled “AI/ML Functions for Affected person Outcomes Prediction and Medical Assist” on Friday, Jan. 27, from 1 to 2 p.m. on the Santa Clara Conference Heart in Santa Clara, Calif. This session is a part of Monitor 2 (AI & Information Sciences in Drug Discovery & Medical Analysis) on Day 3 of the annual convention.
The panel can be moderated by Alex Sherman, a principal affiliate in Neurology at Harvard Medical Faculty and director of the Heart for Innovation and Bioinformatics on the Neurological Medical Analysis Institute at Massachusetts Common Hospital (MGH). Along with Dr. Donoghue, confirmed panelists embrace:
- Indu Navar, EverythingALS
- Nuray Yurt, Novartis Oncology
- Marie Abele Bind, MGH/Harvard Medical Faculty
Dr. Donoghue accomplished his medical diploma from the Well being Sciences & Know-how program at Harvard Medical Faculty and his Ph.D. in neuroscience from MIT, the place his analysis targeted on computational neurophysiology and the consequences of neuroactive compounds on mind community exercise. He co-founded Beacon Biosignals in 2019.
Dr. Donoghue will talk about Beacon’s progress utilizing machine studying to investigate epileptiform burden and sleep endpoints derived from electroencephalogram (EEG) recordings. Stratifying sufferers primarily based on these insights supplies a extra detailed understanding of a affected person’s situation, and might result in extra focused and efficient therapy plans.
The world’s main computational neurodiagnostics firm, Beacon harnesses machine studying that unlocks the facility of EEG knowledge to advance precision medicines for neurologic and psychiatric problems.
About Beacon Biosignals
Beacon’s machine studying platform for EEG allows and accelerates new remedies that rework the lives of sufferers with neurological, psychiatric or sleep problems. Via novel machine studying algorithms, giant scientific datasets, and advances in software program engineering, Beacon Biosignals empowers biopharma firms with unparalleled instruments for efficacy monitoring, affected person stratification, and scientific trial endpoints from mind knowledge. For extra info, go to https://beacon.bio/. For careers, go to https://beacon.bio/careers; for partnership inquiries, go to https://beacon.bio/contact. Observe us on Twitter (@Biosignals) or LinkedIn (https://www.linkedin.com/firm/beacon-biosignals).
Amendola Communications for Beacon Biosignals
SOURCE Beacon Biosignals